Company intelligence / Profile preview

OT4B

Ownership: Private
Development stage: Phase 3

Overview

OT4B is conducting a Phase III clinical trial called OTBB3 for oxytocin treatment in Prader-Willi syndrome. The company is developing oxytocin as the first treatment for patients with this rare disease.

Therapeutic areas: Rare Diseases
Modalities: Peptide (oxytocin)
Industry: Biotech

Drug pipeline

1 asset

oxytocin

Phase 3

Indications: Prader-Willi Syndrome

Partnerships

Toulouse University HospitalCREAPHARM

Beyond the preview

Go deeper on OT4B.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OT4B.

Explore the full profile